Capital Group Private Client Services, Inc. Gilead Sciences, Inc. Transaction History

Capital Group Private Client Services, Inc.

$9.94 Billion
Q3 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$76.01 - $86.7 $15,354 - $17,513	-202 Reduced 1.46%	13,643 $1.05 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $1,082 - $1,233	14 Added 0.1%	13,845 $1.15 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $47,861 - $68,712	-768 Reduced 5.26%	13,831 $1.19 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $4,822 - $5,508	-81 Reduced 0.55%	14,599 $901,000
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $2.5 Million - $2.82 Million	-43,305 Reduced 74.68%	14,680 $907,000
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $44.6 Million - $55.9 Million	-770,325 Reduced 93.0%	57,985 $3.45 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $3.01 Million - $3.42 Million	-46,450 Reduced 5.31%	828,310 $60.1 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $59.2 Million - $63.9 Million	874,760 New	874,760 $61.1 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11.2 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.7 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7.09 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.72 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.57 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Group Private Client Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital Group Private Client Services, Inc. with notifications on news.

Account